DEA Opens Applications for Federal Protections for Medical Cannabis Businesses

The Drug Enforcement Administration (DEA) has announced it will begin accepting applications from medical cannabis businesses seeking federal protections this week, marking a pivotal step in the Trump administration's ongoing cannabis rescheduling process. This initiative is expected to provide a new layer of legitimacy and security for operators in the medical marijuana sector, a move that comes as marijuana reform continues to gain widespread national support. According to White House Press Secretary Karoline Leavitt, the administration is advancing with rescheduling because it is “overwhelmingly popular with the vast majority of Americans” and will benefit those who need cannabis for medical treatment

The momentum behind federal cannabis reform is influencing state-level policy as well. In Tennessee, Governor Bill Lee signed a bill blocking an automatic review that could have led to the legalization of medical cannabis under state law following federal rescheduling. Meanwhile, Indiana Governor Mike Braun has directed state agencies to engage with medical cannabis advocates as the federal changes take effect. These actions highlight the complex interplay between federal initiatives and state responses, as states adjust their policies in response to shifting federal stances

Advocacy groups are weighing in on the broader impact of these federal moves. Steph Sherer of Americans for Safe Access argued that federal cannabis rescheduling could dismantle longstanding discriminatory policies affecting patients in housing, employment, and healthcare. In a recent op-ed, Sherer emphasized, “Federal cannabis rescheduling will upend policies discriminating against patients in housing, employment and healthcare.” This perspective is echoed by others in the industry who see rescheduling as a catalyst for more equitable treatment of medical cannabis users

At the federal level, related policy discussions are expanding beyond cannabis. The Food and Drug Administration (FDA) has highlighted its work on accelerating treatment development for post-traumatic stress disorder, including research into psychedelic drugs. Lawmakers such as Sen. Rand Paul are also advocating for continued access to hemp-derived CBD, with Paul tweeting, “Good work by @POTUS protecting continued research and access to alternative treatments with hemp-derived CBD.” These developments indicate a broader shift toward exploring alternative therapies and ensuring patient access to a wider range of medicinal products

Industry and market dynamics are also evolving in response to these regulatory changes. Canadian officials recently reported C$440.5 million in legal cannabis sales for February, while U.S. companies such as TerrAscend Corp. announced robust revenue expectations. Meanwhile, states like Minnesota and Washington are actively proposing changes to cannabis tax laws and licensing fees, signifying ongoing adjustments as the market adapts to new federal guidelines. The Vermont Cannabis Control Board’s legal counsel even suggested that federal rescheduling could “turbocharge” the state’s medical marijuana industry

From the OG Lab newsroom perspective, the DEA’s move to grant federal protections to medical cannabis businesses represents a significant milestone for the U.S. cannabis industry. This development not only signals growing federal acceptance but also sets the stage for further regulatory and market transformation. Stakeholders should watch closely as states and advocacy groups respond, and as federal agencies continue to shape the future landscape of medical cannabis and related therapies